Get the Stockscreener App
0.7536
1.58%
-0.0121
Pre-market:
.75
-0.0036
-0.48%
Xilio Therapeutics Inc stock is traded at $0.7536, with a volume of 194.00K.
It is down -1.58% in the last 24 hours and up +6.29% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.7657
Open:
$0.774
24h Volume:
194.00K
Relative Volume:
0.35
Market Cap:
$39.06M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2546
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+1.67%
1M Performance:
+6.29%
6M Performance:
-6.64%
1Y Performance:
-6.96%
1-Day Range:
$0.7503
$0.7748
1-Week Range:
$0.7105
$0.7787
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7536 | 39.68M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Risks Report: Is Xilio Therapeutics Inc attractive for institutional investorsJuly 2025 Institutional & Risk Managed Investment Entry Signals - خودرو بانک
Detecting price anomalies in Xilio Therapeutics Inc. with AIMarket Growth Review & High Conviction Investment Ideas - newser.com
Leading vs lagging indicators on Xilio Therapeutics Inc. performanceTrade Volume Summary & Daily Stock Trend Watchlist - newser.com
Ranking Xilio Therapeutics Inc. among high performing stocks via toolsJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - newser.com
Is Xilio Therapeutics Inc. trending in predictive chart modelsEarnings Risk Report & Verified Swing Trading Watchlists - newser.com
Relative strength of Xilio Therapeutics Inc. in sector analysisJuly 2025 Recap & Capital Protection Trade Alerts - newser.com
Applying chart zones and confluence areas to Xilio Therapeutics Inc.CEO Change & Reliable Price Action Trade Plans - newser.com
Technical Analysis: Will Xilio Therapeutics Inc. benefit from rising consumer demandWeekly Profit Analysis & Weekly Stock Breakout Alerts - خودرو بانک
Published on: 2025-09-17 11:22:32 - خودرو بانک
Aug Weekly: Can Sky Harbour Group Corporation expand its profit marginsTrade Risk Assessment & Real-Time Stock Entry Alerts - خودرو بانک
Is Xilio Therapeutics Inc. a candidate for recovery playTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
Analyst Downgrade: Is Xilio Therapeutics Inc benefiting from innovation trends2025 Growth vs Value & AI Driven Stock Reports - خودرو بانک
Is Xilio Therapeutics Inc. showing signs of accumulationWeekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Chart overlay techniques for tracking Xilio Therapeutics Inc.Analyst Upgrade & Risk Controlled Daily Trade Plans - newser.com
Is Xilio Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Market Mood & Real-Time Volume Trigger Notifications - newser.com
Aug Mood: Is Xilio Therapeutics Inc stock a smart retirement pickPortfolio Risk Summary & Detailed Earnings Play Alerts - خودرو بانک
Pullback Watch: Is Xilio Therapeutics Inc. forming a double bottomProduct Launch & Intraday High Probability Alerts - خودرو بانک
What high frequency data says about Xilio Therapeutics Inc.Quarterly Trade Report & Daily Growth Stock Tips - newser.com
How to track smart money flows in Xilio Therapeutics Inc.Entry Point & Verified Short-Term Plans - newser.com
How high can Xilio Therapeutics Inc. stock goTrade Ideas & Fast Moving Trade Plans - newser.com
Real time breakdown of Xilio Therapeutics Inc. stock performanceWeekly Profit Recap & AI Optimized Trade Strategies - Newser
Xilio Therapeutics Inc. stock retracement – recovery analysisQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
News impact scoring models applied to Xilio Therapeutics Inc.July 2025 Retail & Free AI Powered Buy and Sell Recommendations - Newser
Using portfolio simulators with Xilio Therapeutics Inc. includedEarnings Overview Summary & Community Consensus Picks - Newser
Trend analysis for Xilio Therapeutics Inc. this weekQuarterly Market Review & Real-Time Volume Trigger Notifications - Newser
Risk adjusted return profile for Xilio Therapeutics Inc. analyzedWeekly Trade Analysis & Technical Buy Zone Confirmations - Newser
Can you recover from losses in Xilio Therapeutics Inc.Portfolio Risk Summary & Low Risk Entry Point Tips - Newser
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued - MSN
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
What is the PEG ratio of Xilio Therapeutics Inc.Trade Exit Summary & Community Consensus Stock Picks - Lancaster City Council
Xilio initiates phase 2 trial for tumor-activated IL-12 therapy - Investing.com
Xilio starts phase 2 trial for XTX301, hits $17.5M milestone in Gilead license deal - MarketScreener
Promising Cancer Drug Shows Partial Responses: Xilio's IL-12 Therapy Advances with $17.5M Gilead Backing - Stock Titan
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - Yahoo Finance
Is Xilio Therapeutics Inc. impacted by rising ratesMarket Activity Recap & Daily Profit Focused Stock Screening - 뉴스영
Will Xilio Therapeutics Inc. benefit from rising consumer demand2025 Risk Factors & Momentum Based Trading Signals - beatles.ru
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):